Trials / Completed
CompletedNCT00185315
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
Open-label, Uncontrolled, Long-term Surveillance Study of Iloprost Aerosol Inhalation Therapy in the Treatment of Patients With Primary or Secondary Pulmonary Hypertension. Follow-up Program for Patients Who Completed 12 Weeks in Study ME97218/300180.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 71 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
Detailed description
This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ventavis (Iloprost, BAYQ6256) | Inhaled iloprost |
Timeline
- Start date
- 2000-02-01
- Completion
- 2005-08-01
- First posted
- 2005-09-16
- Last updated
- 2010-04-20
Locations
16 sites across 7 countries: Belgium, France, Italy, Netherlands, Poland, Portugal, Spain
Source: ClinicalTrials.gov record NCT00185315. Inclusion in this directory is not an endorsement.